Answers are grounded in this paper and cite their sources.
Retrospective cohort evaluates GLP-1 RAs for weight regain post-RYGB, indicating potential metabolic benefits.
Background Weight regain after Roux-en-Y gastric bypass (RYGB) can diminish the long-term benefits of bariatric surgery. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a pharmacologic option to counter postoperative weight recurrence. Aims To evaluate the efficacy, tolerability, and impact on quality of life of GLP-1 RAs in patients with weight regain after RYGB. Methods In this retrospective cohort, 70 patients with ≥15% weight regain after RYGB received GLP-1 RA therapy and were followed for 18 months. Primary endpoints were changes in body weight and Body Index Mass (BMI); secondary endpoints included remission of metabolic comorbidities and quality of life assessed by the BAROS score. Results Median total body weight loss (TBWL) reached 12.8% at 18 months. Remission of type 2 diabetes mellitus (T2DM) was observed in 96.6% at 12 months, hypertension remission in 80%, and dyslipidaemia remission in 86%. Quality of life scores improved significantly. Therapy discontinuation occurred in 7.1% of patients. Conclusion GLP-1 RAs appear effective and well tolerated in managing weight regain after RYGB, delivering metabolic improvements and measurable enhancement in quality of life. The durability of these effects beyond treatment requires further investigation.
No takes yet. Share an insight, caveat, or question.
Canal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: